A
Andrew Parker
Researcher at St. Vincent's Health System
Publications - 24
Citations - 1180
Andrew Parker is an academic researcher from St. Vincent's Health System. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 8, co-authored 23 publications receiving 562 citations. Previous affiliations of Andrew Parker include University of New South Wales & Garvan Institute of Medical Research.
Papers
More filters
Journal ArticleDOI
A single-cell and spatially resolved atlas of human breast cancers.
Sunny Z. Wu,Sunny Z. Wu,Ghamdan Al-Eryani,Ghamdan Al-Eryani,Daniel L. Roden,Daniel L. Roden,Simon Junankar,Simon Junankar,Kate Harvey,Alma Andersson,Aatish Thennavan,Chenfei Wang,James R. Torpy,James R. Torpy,Nenad Bartonicek,Nenad Bartonicek,Taopeng Wang,Taopeng Wang,Ludvig Larsson,Dominik C. Kaczorowski,Neil I. Weisenfeld,Cedric Uytingco,Jennifer Chew,Zachary Bent,Chia-Ling Chan,Vikkitharan Gnanasambandapillai,Charles-Antoine Dutertre,Charles-Antoine Dutertre,Laurence Gluch,Mun N. Hui,Jane Beith,Andrew Parker,Andrew Parker,Elizabeth Robbins,Davendra Segara,Caroline Cooper,Caroline Cooper,Cindy Mak,Belinda Chan,Sanjay Warrier,Florent Ginhoux,Florent Ginhoux,Florent Ginhoux,Ewan K.A. Millar,Ewan K.A. Millar,Ewan K.A. Millar,Joseph E. Powell,Joseph E. Powell,Stephen R. Williams,X. Shirley Liu,Sandra A O'Toole,Elgene Lim,Elgene Lim,Elgene Lim,Joakim Lundeberg,Charles M. Perou,Alexander Swarbrick,Alexander Swarbrick +57 more
TL;DR: In this paper, a single-cell and spatially resolved transcriptomics analysis of human breast cancers is presented, which reveals recurrent neoplastic cell heterogeneity and heterotypic interactions play central roles in disease progression.
Journal ArticleDOI
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Alexander Drilon,Alexander Drilon,Ramamoorthy Nagasubramanian,James F. Blake,Nora Ku,Brian B. Tuch,Kevin Ebata,Steve Smith,Veronique Lauriault,Kolakowski Gabrielle R,Barbara J. Brandhuber,Paul D. Larsen,Karyn Bouhana,Shannon L. Winski,R. Hamor,Wen-I Wu,Andrew Parker,Tony Morales,Francis X. Sullivan,Walter E. DeWolf,Lance Wollenberg,Paul Gordon,Dorothea N. Douglas-Lindsay,Maurizio Scaltriti,Ryma Benayed,Sandeep Raj,Bethany Hanusch,Alison M. Schram,Philip Jonsson,Michael F. Berger,Michael F. Berger,Jaclyn F. Hechtman,Jaclyn F. Hechtman,Barry S. Taylor,Steve Andrews,S. Michael Rothenberg,David M. Hyman,David M. Hyman +37 more
TL;DR: LOXO-195 abrogated resistance in TRK fusion-positive cancers that acquired kinase domain mutations, a shared liability with all existing TRK TKIs, establishes a role for sequential treatment by demonstrating continued TRK dependence and validates a paradigm for the accelerated development of next-generation inhibitors against validated oncogenic targets.
Journal ArticleDOI
Stromal cell diversity associated with immune evasion in human triple-negative breast cancer.
Sunny Z. Wu,Sunny Z. Wu,Daniel L. Roden,Daniel L. Roden,Chenfei Wang,Holly Holliday,Holly Holliday,Kate Harvey,Aurélie Cazet,Aurélie Cazet,Kendelle J. Murphy,Kendelle J. Murphy,Brooke A. Pereira,Brooke A. Pereira,Ghamdan Al-Eryani,Ghamdan Al-Eryani,Nenad Bartonicek,Nenad Bartonicek,Rui Hou,James R. Torpy,James R. Torpy,Simon Junankar,Simon Junankar,Chia Ling Chan,Chuan En Lam,Mun N. Hui,Laurence Gluch,Jane Beith,Andrew Parker,Elizabeth Robbins,Davendra Segara,Cindy Mak,Caroline Cooper,Caroline Cooper,Sanjay Warrier,Alistair R. R. Forrest,Joseph E. Powell,Joseph E. Powell,Sandra A O'Toole,Sandra A O'Toole,Thomas R. Cox,Thomas R. Cox,Paul Timpson,Paul Timpson,Elgene Lim,Elgene Lim,Elgene Lim,X. Shirley Liu,Alexander Swarbrick,Alexander Swarbrick +49 more
TL;DR: Investigation of gene signatures from inflammatory‐CAFs and differentiated‐PVL cells in independent TNBC patient cohorts revealed strong associations with cytotoxic T‐cell dysfunction and exclusion, respectively, presenting promising candidates for new therapeutic strategies in the treatment of TNBCs.
Journal ArticleDOI
Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer.
Simon Junankar,Gemma Shay,Julie Jurczyluk,Naveid A. Ali,Jenny Down,Nicholas Pocock,Andrew Parker,Akira Nguyen,Shuting Sun,Boris A. Kashemirov,Charles E. McKenna,Peter I. Croucher,Alexander Swarbrick,Katherine N. Weilbaecher,Tri Giang Phan,Michael J. Rogers +15 more
TL;DR: It is provided unequivocal evidence that bisphosphonates target TAMs, but not tumor cells, to exert their extraskeletal effects, offering a rationale for use in patients with early disease.
Journal ArticleDOI
Memory B cells are reactivated in subcapsular proliferative foci of lymph nodes.
Imogen Moran,Imogen Moran,Akira Nguyen,Akira Nguyen,Weng Hua Khoo,Weng Hua Khoo,Danyal Butt,Katherine Bourne,Clara Young,Jana R. Hermes,Maté Biro,Gary Gracie,Cindy S. Ma,Cindy S. Ma,C Mee Ling Munier,Fabio Luciani,Fabio Luciani,John Zaunders,John Zaunders,Andrew Parker,Anthony D. Kelleher,Anthony D. Kelleher,Stuart G. Tangye,Stuart G. Tangye,Peter I. Croucher,Peter I. Croucher,Robert Brink,Robert Brink,Mark Read,Tri Giang Phan,Tri Giang Phan +30 more
TL;DR: It is shown that memory B cells localise to lymph node subcapsular proliferative foci (SPF), which have distinct properties from the germinal centre, for rapid expansion and the induction of B memory responses.